Lv31
240 积分 2024-07-02 加入
Requirements for operational cure in multiple myeloma
3天前
已完结
Role of new treatment approaches in defining treatment goals in multiple myeloma--the ultimate goal is extended survival
17天前
已完结
Use of CD38 Antibodies in High-Risk Newly Diagnosed Multiple Myeloma: A Meta-Analysis
28天前
已完结
Minimal residual disease response-adapted therapy in newly diagnosed multiple myeloma (MASTER): final report of the multicentre, single-arm, phase 2 trial
29天前
已完结
Minimal residual disease response-adapted therapy in newly diagnosed multiple myeloma (MASTER): final report of the multicentre, single-arm, phase 2 trial
29天前
已完结
High-risk genomic consensus validation for patients with newly diagnosed multiple myeloma using next-generation sequencing
1个月前
已完结
P875: REPLACING STEROIDS IN TRANSPLANT-INELIGIBLE MULTIPLE MYELOMA: THE PHASE 2 ISATUXIMAB-BORTEZOMIB-LENALIDOMIDE-DEXAMETHASONE REST STUDY
1个月前
已完结
Isatuximab, bortezomib, lenalidomide, and limited dexamethasone in patients with transplant-ineligible multiple myeloma (REST): a multicentre, single-arm, phase 2 trial
1个月前
已完结
Frailty in Older Adults With Multiple Myeloma: A Study of US Veterans
3个月前
已完结
皖公网安备34019202002308
